Abstract
Aim The purpose of this research is to identify the mechanisms of Shen-Qi compound formula (SQC), a traditional Chinese medicine (TCM), for treating diabetes mellitus (DM) using system pharmacology. Methods The active components and therapeutic targets were identified, and these targets were analyzed using gene ontology (GO) enrichment analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, and protein-protein interaction (PPI) analysis. Finally, an integrated pathway was constructed to show the mechanisms of SQC. Results A total of 282 active components and 195 targets were identified through a database search. The component-target network was constructed, and the key components were screened out according to their degree. Through the GO, PPI, and KEGG analyses, the mechanism network of SQC treating DM was constructed. Conclusions This study shows that the mechanisms of SQC treating DM are related to various pathways and targets. This study provides a good foundation and basis for further in-depth verification and clinical application.
Highlights
Diabetes mellitus (DM) is an endocrine and metabolic disease characterized by persistent hyperglycemia
Search and Screening of Chemical Constituents. e workflow for this network pharmacology study can be seen in Figure 1. e screening of the active ingredients of the herbal medicines in SC was conducted on the platform of the traditional Chinese medicine (TCM) System Pharmacology database (TCMSP) and SymMap
We excluded the pathways that were unrelated to diabetes among the top 25 pathways. e rest of the pathways were considered to be the main mechanisms. en, we looked up the Kyoto Encyclopedia of Genes and Genomes (KEGG) database to understand the specific processes of these mechanisms
Summary
Diabetes mellitus (DM) is an endocrine and metabolic disease characterized by persistent hyperglycemia. Its main clinical manifestations include polydipsia, polyphagia, polyuria, and weight change [1]. Ere are many chronic complications in the later stage of DM, including macrovascular disease, microvascular disease, and diabetic neuropathy [4]. The treatment of DM has long been researched, the management of DM and its chronic complications are still big challenges in clinical practice [5,6,7,8,9]. Erapeutic agents are mainly composed of insulin and oral hypoglycemic medicines. Insulin is the most effective hypoglycemic agent, but it increases the risk of hypoglycemia, which in turn increases the risk of cardiovascular disease and other complications [10, 11]. Oral hypoglycemic agents cannot achieve the desired state in many cases, which may be due to their adverse reactions or clinical inertia. erefore, new means of treatment are needed
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Evidence-Based Complementary and Alternative Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
